Drugs and FDA
FDA approves AbbVie’s Juvmo for adults with Parkinson’s disease
Juvmo is an oral treatment approved for adults with Parkinson’s disease, taken once daily with or without levodopa.
The FDA has approved AbbVie’s tavapadon, sold as Juvmo, for adults with Parkinson’s disease. AbbVie said the oral tablet is taken once daily, with or without levodopa. It is the first approved Parkinson’s dopamine agonist designed to selectively target D1/D5 receptors, while available agonists mainly target D2/D3 receptors, MedPage Today and Healio reported.
AbbVie’s TEMPO trials tested tavapadon alone in early disease and with levodopa in patients with motor fluctuations. In TEMPO-1, Healio reported that at week 26 the 5 mg and 15 mg groups had score decreases of 9.7 points and 10.2 points on combined Movement Disorder Society-Unified Parkinson’s Disease Rating Scale parts II and III, compared with a 1.8-point increase with placebo. In TEMPO-3, daily “on time” without troublesome dyskinesia increased by 1.7 hours with tavapadon and 0.6 hours with placebo, according to Healio. AbbVie plans to make the drug available to U.S. patients in October, MedPage Today reported. Common adverse effects included nausea, dizziness and headache.
